Augusto Maria Lavalle Cobo

Dr. Augusto Maria Lavalle Cobo


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2021 in Cells
Verified
Journal Article
Open access
PDF file
WMWalter Masson
Walter Masson
ACAugusto Maria Lavalle Cobo
Augusto Maria Lavalle Cobo
JNJuan Patricio Nogueira
Juan Patricio Nogueira
(1) Sodium–glucose cotransporter-2 inhibitors (SGLT2-i) reduce adipose tissue and cardiovascular events in patients with type 2 diabetes (T2D). Accumulation of epicardial adipose tissue (EAT) is associated with increased cardio-metabolic risks and obstructive coronary disease events in patients with T2D. (2) We performed a systematic review and meta-analysis of SGLT2-i therapy on T2D patients, reporting data on changes in EAT after searching the PubMed/MEDLINE, Embase, Science Direct, Scopus, Google Scholar, and Cochrane databases. A random effects or fixed effects model meta-analysis was then applied. (3) Results: A total of three studies (n = 64 patients with SGLT2-i, n = 62 with standard therapy) were included in the final analysis. SGLT2 inhibitors reduced EAT (SMD: −0.82 (−1.49; −0.15); p < 0.0001). An exploratory analysis showed that HbA1c was significantly reduced with SGLT2-i use, while body mass index was not significantly reduced with this drug. (4) Conclusions: This meta-analysis suggests that the amount of EAT is significantly reduced in T2D patients with SGLT2-i treatment.

18 June 2024 in Journal of the American Heart Association
Verified
Journal Article
Open access
ODOmar Dzaye
Omar Dzaye
ARAlexander C. Razavi
Alexander C. Razavi
ZDZeina A. Dardari
Zeina A. Dardari
KNKhurram Nasir
Khurram Nasir
KMKunihiro Matsushita
Kunihiro Matsushita
MBMichael J. Blaha
Michael J. Blaha
Background: Coronary artery calcium testing using noncontrast cardiac computed tomography is a guideline‐indicated test to help refine eligibility for aspirin in primary prevention. However, access to cardiac computed tomography remains limited, with carotid ultrasound used much more often internationally. We sought to update the role of aspirin allocation in primary prevention as a function of subclinical carotid atherosclerosis. Methods and Results: The study included 11 379 participants from the MESA (Multi‐Ethnic Study of Atherosclerosis) and ARIC (Atherosclerosis Risk in Communities) studies. A harmonized carotid plaque score (range, 0–6) was derived using the number of anatomic sites with plaque from the left and right common, bifurcation, and internal carotid artery on ultrasound. The 5‐year number needed to treat and number needed to harm as a function of the carotid plaque score were calculated by applying a 12% relative risk reduction in atherosclerotic cardiovascular disease (ASCVD) events and 42% relative increase in major bleeding events related to aspirin use, respectively. The mean age was 57 years, 57% were women, 23% were Black, and the median 10‐year ASCVD risk was 12.8%. The 5‐year incidence rates (per 1000 person‐years) were 5.5 (4.9–6.2) for ASCVD and 1.8 (1.5–2.2) for major bleeding events. The overall 5‐year number needed to treat with aspirin was 306 but was 2‐fold lower for individuals with carotid plaque versus those without carotid plaque (212 versus 448). The 5‐year number needed to treat was less than the 5‐year number needed to harm when the carotid plaque score was ≥2 for individuals with ASCVD risk 5% to 20%, whereas the presence of any carotid plaque demarcated a favorable risk–benefit for individuals with ASCVD risk >20%. Conclusions: Quantification of subclinical carotid atherosclerosis can help improve the allocation of aspirin therapy.

1 July 2021 in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
Verified
Journal Article
Closed access
WMWalter Masson
Walter Masson
MLMartín Lobo
Martín Lobo
LBLeandro Barbagelata
Leandro Barbagelata
ACAugusto Maria Lavalle Cobo
Augusto Maria Lavalle Cobo
GMGraciela Molinero
Graciela Molinero

1 April 2021 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
WMWalter Masson
Walter Masson
MLMartín Lobo
Martín Lobo
DSDaniel Siniawski
Daniel Siniawski
GMGerardo Masson
Gerardo Masson
ACAugusto Maria Lavalle Cobo
Augusto Maria Lavalle Cobo
GMGraciela Molinero
Graciela Molinero

5 April 2024 in European Cardiology Review
Verified
Journal Article
Open access
PDF file
DSDirk Sibbing
Dirk Sibbing
MBMichael J Blaha
Michael J Blaha
RCRajinder Chawla
Rajinder Chawla
ACAugusto Maria Lavalle Cobo
Augusto Maria Lavalle Cobo
AKAmit Kishore
Amit Kishore
ZSZhongwei Shi
Zhongwei Shi
Background: Low-dose aspirin lowers cardiovascular event risk; dual-pathway inhibition (DPI) using low-dose aspirin with low-dose rivaroxaban may reduce this risk further. A systematic literature review and meta-analysis compared the efficacy, safety and net clinical benefit (NCB) of DPI with aspirin. Methods: PubMed and Embase were searched for randomised controlled trials reporting clinical efficacy, safety and NCB of DPI compared with aspirin alone in patients with coronary artery disease (CAD) and/or peripheral artery disease. Six articles representing four trials were included. Results: DPI versus aspirin alone significantly reduced major adverse cardiovascular events (HR 0.77; 95% CI [0.69–0.87]; p<0.01), increased International Society on Thrombosis and Haemostasis major bleeding events (HR 1.67; 95% CI [1.37–2.02]; p<0.01) and resulted in a significant NCB (HR 0.79; 95% CI [0.70–0.90]; p<0.01). Conclusion: These results underscore the potential benefit of DPI in patients with CAD, including those in the immediate post-acute coronary syndrome stage and with established CAD, as well as patients with peripheral artery disease.

1 January 2024 in Journal of Lipid and Atherosclerosis
Verified
Journal Article
Open access
PDF file
WMWalter Masson
Walter Masson
PCPablo Corral
Pablo Corral
JNJuan Patricio Nogueira
Juan Patricio Nogueira
ACAugusto Maria Lavalle Cobo
Augusto Maria Lavalle Cobo
Masson W, et al. J Lipid Atheroscler. 2024 May;13(2):111-121. https://doi.org/10.12997/jla.2024.13.2.111